TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

A$40 Million (aud)

Botanix Pharmaceuticals


Sole Placement Agent, July 2019

Botanix Pharmaceuticals
Botanix Pharmaceuticals is a clinical stage cannabinoid company based in Australia committed to the development of pharmaceutical products treating a range of dermatological conditions. The active ingredient contained in Botanix’s products is a synthetic form of cannabidiol (CBD). The Company’s focus on the development of safe and effective topical treatments for acne, psoriasis, atopic dermatitis and other skin conditions, addressing treatment targets such as inflammation, deterioration of the skin barrier, skin cell proliferation, pruritus (itch), excess sebum production and bacterial infection. The Company has an exclusive license to use proprietary drug delivery system Permetrex for direct skin delivery of active pharmaceuticals in all skin disease.